Stancorp Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Stancorp Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$3K	Buy	+7	New	+$2.97K	﹤0.01%	592

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stancorp Investment Advisers's REGN Position: Q1 2015 in Review

Stancorp Investment Advisers opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2015: 7 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #592 among its holdings.

508 funds tracked by Wall St. Rank hold REGN as of Q1 2015.

Stancorp Investment Advisers held 7 shares of Regeneron Pharmaceuticals worth $3K as of Q1 2015.
Regeneron Pharmaceuticals was a new Stancorp Investment Advisers position in Q1 2015.
Regeneron Pharmaceuticals made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #592 holding.
508 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.